ClinicalTrials.gg
CompletedNCT01692834Updated Aug 1, 2014

A Study to Compare the Bioavailability and Pharmacokinetics of Cyclosporine After Intravenous Administration of NEUROSTAT®, a CREMOPHOR® EL-free Lipid Emulsion, and SANDIMMUNE® Injection (a Suspension of Cyclosporine in CREMOPHOR® EL) in Healthy Volunteers

A Phase 1 interventional study of Sandimmune® Injection and NeuroSTAT® in Healthy, sponsored by NeuroVive Pharmaceutical AB. Completed at 1 site in South Africa. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-08-01.

Sponsored by NeuroVive Pharmaceutical AB (part of Pharming Group N.V.) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

To compare the bioavailability, pharmacokinetic profiles and the tolerability of two formulations of intravenous cyclosporine in healthy volunteers.

Read the detailed description

Participants were randomized into two treatment sequences: the test product followed by the reference product or vice versa. There was a washout period set to 14-21 days between the first and second treatment period. Through an indwelling IV cannula, the subjects received either 5 mg/kg NeuroSTAT® (test) or 5 mg/kg Sandimmune® (reference), infused at a constant rate over 4 h with a syringe pump. A total of 22 blood samples for Cyclosporine analysis were obtained pre-dose and at pre specified time points with last sample 48 h after start of infusion.

02

Conditions studied

  • Healthy

Keywords

  • bioequivalence
  • pharmacokinetics
  • tolerability
  • safety
  • ciclosporin
  • cyclosporine
  • cyclosporine A
  • Sandimmune
  • Sandimmun
  • CicloMulsion
  • NeuroSTAT
03

In context

Lead sponsor

NeuroVive Pharmaceutical AB is the lead sponsor of 2 studies on the registry; none are open to participants now.

First submitted before NeuroVive Pharmaceutical AB became part of Pharming Group N.V..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy male and female subjects 18 to \< 56 years of age.
  2. Caucasian and Non-Caucasian subjects.
  3. Body mass within 15% of the ideal mass in relation to height and age (this relates to a [BMI] of 19 - 33 kg/m2).
  4. Body mass not less than 60 kg and not more than 100 kg.
  5. Findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the laboratory reference ranges for the relevant laboratory tests (unless the investigator considered the deviation to be irrelevant for the purpose of the study).
  6. Normal 12-lead and vital signs, or abnormalities which the investigator did not consider a disqualification for participation in the study.
  7. Willingness to undergo pre-, interim- and post-study physical examinations, vital signs and laboratory investigations.
  8. Ability to comprehend and willingness to have signed both statements of (for screening and period-related procedures).
  9. Non-smoker or past smoker who had stopped the use of any form of tobacco, including snuff or similar products, at least 3 months before the first administration of study medication.
  10. Female subjects of , but who were not pregnant, not lactating and who were either abstaining from sexual activity or using medically acceptable and reliable methods of for the duration of the study. Examples of reliable methods of contraception included tubal ligation, hysterectomy, intrauterine device, or a barrier method combined with a spermicide. The use of hormonal contraceptives (including a hormonal intrauterine device) was not allowed. Females not of childbearing potential may have been included if they had no menstrual period for one year and were considered as . A pregnancy test was performed prior to each cyclosporine dosing to all women of childbearing potential.

Exclusion criteria

Exclusion Criteria:

  1. Evidence of psychiatric disorder, antagonistic personality, poor motivation, emotional or intellectual problems likely to have limited the validity of consent to participate in the study or limited the ability to comply with protocol requirements.
  2. History of, or current compulsive alcohol abuse (> 10 drinks weekly), or regular exposure to other substances of abuse.
  3. Use of any medication, prescribed or over-the-counter, within 2 weeks prior to the first administration of study medication (within 2 weeks prior to dosing in Treatment period 2 for Cohort 2) except if this would not have affected the outcome of the study in the opinion of the investigator.
  4. Females taking oral or transdermal hormonal within 14 days preceding dosing or having used implanted or injected hormonal contraceptives within 6 months prior to dosing.
  5. Participation in another study with an experimental drug, where the last administration (of previous study medication) was within 12 weeks before the first administration of study medication.
  6. Treatment within the previous 3 months with any drug with a well-defined potential for adversely affecting a major organ or system.
  7. A major illness during the 3 months before commencement of the screening period.
  8. History of to the study medication, carrier substances, or any related medication.
  9. History of any type of .
  10. Tendency toward recurrent infections, known untreated parasitic infection, or history of primary or secondary immunodeficiency.
  11. History of allergy to soybeans or soy products.
  12. History of allergy to eggs or egg products.
  13. History of bronchial asthma or any other bronchospastic diseases.
  14. History of epilepsy.
  15. History of porphyria.
  16. History of psoriasis.
  17. History of atopic dermatitis.
  18. History of elevated cholesterol levels of above 6.5 mmol/L.
  19. History of gout.
  20. History of rheumatoid arthritis.
  21. History or evidence of kidney disease or renal failure.
  22. Relevant history or laboratory or clinical findings indicative of acute or chronic disease, likely to have influenced study outcome.
  23. Total concentration, which exceeds 10% of normal laboratory ranges (4-30 μmol/L).
  24. Donation or loss of blood equal to or exceeding 500 mL during the 8 weeks before the first administration of study medication.
  25. Diagnosis of hypotension made during the screening period.
  26. Diagnosis of hypertension made during the screening period or current diagnosis of hypertension.
  27. Resting pulse rate of > 100 beats per minute or \< 40 beats per minute during the screening period, either supine or standing.
  28. Positive testing for and and/or .
  29. Positive urine screen for drugs of abuse.
  30. Positive urine screen for tobacco use.
  31. A serum pregnancy test for females (beta human chorionic gonadotropin [β-HCG]) either positive or not performed or lactation.
  32. Vaccination with any vaccine (including live, attenuated virus or bacterial vaccines) within 4 weeks of first dose or planning to have had a vaccination within 3 months after the second dose.
  33. Subjects with close family members (spouse/partner/children) receiving a during the study, or within 3 months after the second dose.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
65 participants (actual)

Study arms

  • Active comparator
    Cyclosporine in Cremophor EL®

    Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.

    Drug: Sandimmune® Injection

  • Active comparator
    Cyclosporine in lipid emulsion

    Dosing 5 mg/kg infused at a constant rate over 4 h with a syringe pump.

    Drug: NeuroSTAT®

Interventions

06

What researchers measure

Primary outcomes

  1. Bioequivalence between test and reference product.

    To compare the bioavailability and pharmacokinetics of a single dose of the test product, NeuroSTAT® 5 mg/mL ready-to-use Cremophor® EL-free cyclosporine with the reference product, Sandimmune® Injection 50 mg/mL Cremophor® EL suspension (each 1 mL diluted in 20 mL saline). For this purpose the pharmacokinetics of cyclosporine was compared during and after intravenous (IV) infusion, over 4 hours, of a single dose of 5 mg/kg of each of the two formulations to healthy subjects. The primary parameters are area under the blood concentration-time curves (AUC) from time zero to time of last measurable concentration (AUC0-last), time zero to infinity (AUC0-∞), time 4 h to infinity (AUC4-∞). Point estimates and 90 % Confidence IntervaI (CI) for the NeuroSTAT®/Sandimmune® geometric mean ratios of all variables are calculated. The two products are considered bioequivalent if the 90 % CI for the primary variables are within the FDA and EMA approved range of 0.8 and 1.25.

    Time frame: Repeated samplings from pre-dose to 48 hours

Secondary outcomes

  1. Tolerability comparison of test and reference product

    To compare the tolerability profiles of the test product, NeuroSTAT® 5 mg/mL ready-to-use Cremophor® EL-free cyclosporine USP/Ph. Eur. lipid emulsion, with the reference product, Sandimmune® Injection (cyclosporine injection, USP) 50 mg/mL Cremophor® EL suspension (each 1 mL diluted in 20 mL saline). The proportions of overall adverse events and adverse events per organ class (as defined by the Medical Dictionary for Regulatory Activities) are compared between NeuroSTAT® and Sandimmune® by means of 95 % CI for the difference between paired proportions and p-values.

    Time frame: From start of study drug administration to last blood sampling at 48 hours

07

Study locations

1 site
  • PAREXEL
    Bloemfontein, 9301, South Africa
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2009, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2012
First posted
Sep 25, 2012
Start
Jun 2009
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Last update
Aug 1, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01692834
Responsible party
Sponsor
First posted
Sep 25, 2012
Start date
Jun 2009
Primary completion
Jan 2010
Completion
Jan 2010
Last update
Aug 1, 2014

Study contacts

Eduard FW Krantz, Dr
principal investigator · Parexel

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion